A Phase 1 interventional study of T-817MA in Healthy and Hepatic Impairment, sponsored by FUJIFILM Toyama Chemical Co., Ltd.. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-24.
Sponsored by FUJIFILM Toyama Chemical Co., Ltd. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective is to determine the single-dose pharmacokinetics (PK) of T-817 and T-817M5 (metabolite of T-817) in subjects with mild, moderate or severe hepatic impairment compared to matched healthy control subjects.
The secondary objective is to determine the safety and tolerability of single-dose T -817MA (Maleate salt of T-817) in subjects with mild, moderate or severe hepatic impairment.
FUJIFILM Toyama Chemical Co., Ltd. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For subjects with mild, moderate or severe hepatic impairment
For Matched Healthy Control Subjects Healthy adult male or female subjects will be matched 1:1 to a specific subject in the mild, moderate, or severe hepatic impairment cohort based upon age, weight, gender, and smoking status
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mild hepatic impairment subjects
Drug: T-817MA
Healthy subjects matched to subjects in Cohort 1
Drug: T-817MA
Moderate hepatic impairment subjects
Drug: T-817MA
Healthy subjects matched to subjects in Cohort 3
Drug: T-817MA
Severe hepatic impairment subjects
Drug: T-817MA
Healthy subjects matched to subjects in Cohort 5
Drug: T-817MA
A single oral dose of 448 mg
Plasma concentrations
Time frame: 8 days
Area under the plasma concentration time curve (AUC)
Time frame: 8 days
Maximum observed plasma concentration (Cmax)
Time frame: 8 days
Time to reach the maximum observed plasma concentration (tmax)
Time frame: 8 days
Apparent terminal elimination rate constant
Time frame: 8 days
Apparent terminal elimination half-life (t½)
Time frame: 8 days
Apparent total plasma clearance of unbound drug after oral (extravascular) administration (CL/F)
Time frame: 8 days
Apparent volume of distribution during the terminal elimination phase after oral (extravascular) administration (Vd/F)
Time frame: 8 days
Metabolite to parent ratio (MPR)
Time frame: 8 days
Number of participants with treatment-related adverse events
Time frame: 8days
Ran from Feb 2016 to primary completion in Aug 2016, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: T-817 maleate
FUJIFILM Toyama Chemical Co., Ltd.